2012 Fiscal Year Final Research Report
Enhancement of effects of WT1 peptide-based immunotherapy for malignant glioma
| Project/Area Number |
22591609
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
TSUBOI Akihiro 大阪大学, 医学(系)研究科(研究院), 教授 (10372608)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HASHIMOTO Naoya 大阪大学, 医学(系)研究科(研究院), 准教授 (90315945)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Keywords | がんワクチン / 脳腫瘍 / 悪性神経膠腫 / WT1 / 癌免疫療法 |
|---|
| Research Abstract |
We previously showed that WT1 immunotherapy is effective for recurrent malignant gliomas on the phase II clinical trial (J Neurosurg, 108(5):963-71, 2008).In this study we examined safety and efficacy of combination therapy with WT1 immunotherapy and Temozolomide (TMZ) for newly diagnosed malignant gliomas on phase I clinical trial and combination therapy of WT1-CTL peptide and WT1-helper peptide for recurrent gliomas . Both treatments were well tolerated and showed promising clinical outcomes.
|
